Clinical Trials in Hypertrophic Cardiomyopathy Therapy: A Comprehensive Analysis of Trials Registered in Global Clinical Databases

References

• Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749–770. doi:10.1161/circresaha.117.311059
   PubMed Web of Science ®Google Scholar
• Maron BJ, Longo DL. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655–668. doi:10.1056/NEJMra1710575
   PubMed Web of Science ®Google Scholar
• Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83–99. doi:10.1016/j.jacc.2014.05.003
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;124(24):2761–2796. doi:10.1161/CIR.0b013e318223e230
   PubMed Web of Science ®Google Scholar
• Kraker J, Viswanathan SK, Knöll R, Sadayappan S. Recent advances in the molecular genetics of familial hypertrophic cardiomyopathy in South Asian descendants. Front Physiol. 2016;7:499. doi:10.3389/fphys.2016.00499
   PubMed Web of Science ®Google Scholar
• Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880–888. doi:10.1038/gim.2014.205
   PubMed Web of Science ®Google Scholar
• Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60(8):705–715. doi:10.1016/j.jacc.2012.02.068
   PubMed Web of Science ®Google Scholar
• Biagini E, Olivotto I, Iascone M, et al. Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. Am J Cardiol. 2014;114(5):769–776. doi:10.1016/j.amjcard.2014.05.065
   PubMed Web of Science ®Google Scholar
• Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res. 2021;128(10):1533–1553. doi:10.1161/circresaha.121.318346
   PubMed Web of Science ®Google Scholar
• Ormerod JO, Frenneaux MP, Sherrid MV. Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy. Nat Rev Cardiol. 2016;13(11):677–687. doi:10.1038/nrcardio.2016.98
   PubMed Web of Science ®Google Scholar
• van der Velden J, Tocchetti CG, Varricchi G, et al. Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc Res. 2018;114(10):1273–1280. doi:10.1093/cvr/cvy147
   PubMed Web of Science ®Google Scholar
• Ho CY, Lakdawala NK, Cirino AL, et al. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 2015;3(2):180–188. doi:10.1016/j.jchf.2014.08.003
   PubMed Web of Science ®Google Scholar
• Sacchetto C, Sequeira V, Bertero E, Dudek J, Maack C, Calore M. Metabolic alterations in inherited cardiomyopathies. J Clin Med. 2019;8(12):2195. doi:10.3390/jcm8122195
   PubMed Web of Science ®Google Scholar
• Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417(1):1–13. doi:10.1042/bj20081386
   PubMed Web of Science ®Google Scholar
• Aoyama R, Takano H, Kobayashi Y, et al. Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using 18F-fluorodeoxyglucose positron emission tomography. PLoS One. 2017;12(11):e0188479. doi:10.1371/journal.pone.0188479
   PubMed Web of Science ®Google Scholar
• Pereira RO, Wende AR, Olsen C, et al. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. J Am Heart Assoc. 2013;2(5):e000301. doi:10.1161/jaha.113.000301
   PubMed Web of Science ®Google Scholar
• Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–2779. doi:10.1093/eurheartj/ehu284
   PubMed Web of Science ®Google Scholar
• Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–2239. doi:10.1161/circulationaha.106.644682
   PubMed Web of Science ®Google Scholar
• Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75(21):2649–2660. doi:10.1016/j.jacc.2020.03.064
   PubMed Web of Science ®Google Scholar
• McNamara JW, Li A, Dos Remedios CG, Cooke R. The role of super-relaxed myosin in skeletal and cardiac muscle. Biophys Rev. 2015;7(1):5–14. doi:10.1007/s12551-014-0151-5
   PubMedGoogle Scholar
• McNamara JW, Li A, Smith NJ, et al. Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes. J Mol Cell Cardiol. 2016;94:65–71. doi:10.1016/j.yjmcc.2016.03.009
   PubMed Web of Science ®Google Scholar
• Lafreniere-Roula M, Bolkier Y, Zahavich L, et al. Family screening for hypertrophic cardiomyopathy: is it time to change practice guidelines? Eur Heart J. 2019;40(45):3672–3681. doi:10.1093/eurheartj/ehz396
   PubMed Web of Science ®Google Scholar
• Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2015;3(11):896–905. doi:10.1016/j.jchf.2015.06.011
   PubMed Web of Science ®Google Scholar
• Wells S, Rowin EJ, Boll G, et al. Clinical profile of nonresponders to surgical myectomy with obstructive hypertrophic cardiomyopathy. Am J Med. 2018;131(6):e235–e239. doi:10.1016/j.amjmed.2017.12.031
   PubMed Web of Science ®Google Scholar
• Grillo MP, Erve JCL, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica. 2019;49(6):718–733. doi:10.1080/00498254.2018.1495856
   PubMed Web of Science ®Google Scholar
• Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292(40):16571–16577. doi:10.1074/jbc.M117.776815
   PubMed Web of Science ®Google Scholar
• Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A. 2018;115(35):E8143–e8152. doi:10.1073/pnas.1809540115
   PubMed Web of Science ®Google Scholar
• Feizabadi M, Fahimnia F, Mosavi Jarrahi A, Naghshineh N, Tofighi S. Iranian clinical trials: an analysis of registered trials in International Clinical Trial Registry Platform (ICTRP). J Evid Based Med. 2017;10(2):91–96. doi:10.1111/jebm.12248
   PubMedGoogle Scholar
• Chen L, Su Y, Quan L, Zhang Y, Du L. Clinical trials focusing on drug control and prevention of ventilator-associated pneumonia: a comprehensive analysis of trials registered on ClinicalTrials.gov. Original Research. Front Pharmacol. 2019;9. doi:10.3389/fphar.2018.01574
   Web of Science ®Google Scholar
• Jacobsen PB, Wells KJ, Meade CD, et al. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012;30(20):2516–2521. doi:10.1200/JCO.2011.39.5186
   PubMed Web of Science ®Google Scholar
• Bhaskar SB. Clinical trial registration: a practical perspective. Indian J Anaesth. 2018;62(1):10–15. doi:10.4103/ija.IJA_761_17
   PubMed Web of Science ®Google Scholar
• Adams M. Chinese research register joins WHO network, raising hopes for improved clinical trials. Bull World Health Organ. 2007;85(9):653–654. doi:10.2471/blt.07.010907
   PubMed Web of Science ®Google Scholar
• Krleza-Jerić K. Clinical trial registration: the differing views of industry, the WHO, and the Ottawa Group. PLoS Med. 2005;2(11):e378. doi:10.1371/journal.pmed.0020378
   PubMed Web of Science ®Google Scholar
• Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DAB. Issues in the registration of clinical trials. JAMA. 2007;297(19):2112–2120. doi:10.1001/jama.297.19.2112
   PubMed Web of Science ®Google Scholar
• Zwierzyna M, Davies M, Hingorani AD, Hunter J. Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005. BMJ. 2018;361:k2130. doi:10.1136/bmj.k2130
   PubMed Web of Science ®Google Scholar
• FDA US. FDA approves new drug to improve heart function in adults with rare heart condition. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition. Accessed June 15, 2023.
   Google Scholar
• Tompkins JDV, Day SM, Jacoby DL, et al. Abstract 14251: peak oxygen consumption is an independent predictor of survival and outcomes in obstructive and non-obstructive Hypertrophic Cardiomyopathy (HCM) patients: results from the International Sarcomeric Human Cardiomyopathies Registry (SHaRe). Circulation. 2018;138(Suppl_1):A14251–A14251. doi:10.1161/circ.138.suppl_1.14251
   Google Scholar
• Contaldi C, Lombardi R, Giamundo A, Betocchi S. Abstract 19346: peak oxygen consumption predicts outcome in hypertrophic cardiomyopathy. Circulation. 2014;130(suppl_2):A19346–A19346. doi:10.1161/circ.130.suppl_2.19346
   Google Scholar
• Saberi S, Day SM. Exercise and hypertrophic cardiomyopathy. Circulation. 2018;137(5):419–421. doi:10.1161/CIRCULATIONAHA.117.029989
   PubMed Web of Science ®Google Scholar
• Ramli FF, Hashim SAS, Raman B, Mahmod M, Kamisah Y. Role of trientine in hypertrophic cardiomyopathy: a review of mechanistic aspects. Pharmaceuticals. 2022;15(9):1145. doi:10.3390/ph15091145
   Web of Science ®Google Scholar
• Chuang C, Collibee S, Ashcraft L, et al. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021;64(19):14142–14152. doi:10.1021/acs.jmedchem.1c01290
   PubMed Web of Science ®Google Scholar
• Maron Martin S, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34–45. doi:10.1016/j.jacc.2022.10.020
   PubMed Web of Science ®Google Scholar
• Wang J, Huang X, Liu H, et al. Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function. Oxid Med Cell Longev. 2022;9(1122494). doi:10.1155/2022/1122494
   Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi:10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568–574. doi:10.1038/s41591-021-01659-1
   PubMed Web of Science ®Google Scholar
• Zakir RM, Folefack A, Saric M, Berkowitz RL. The use of midodrine in patients with advanced heart failure. Congestive Heart Failure. 2009;15(3):108–111. doi:10.1111/j.1751-7133.2008.00042.x
   PubMedGoogle Scholar
• Lafitte S, Peyrou J, Reynaud A, et al. Midodrine hydrochloride and unexpected improvement in hypertrophic cardiomyopathy symptoms. Arch Cardiovasc Dis. 2016;109(3):223–225. doi:10.1016/j.acvd.2015.11.005
   PubMed Web of Science ®Google Scholar
• Tremaine L, Al-Fayoumi S, van de Wetering J, van Iersel T, Patel J, Chamberlin P. Abstract 10372: a clinical drug-drug interaction study of Imb-1018972, a novel investigational cardiac mitotrope in phase 2 development for the treatment of myocardial ischemia and hypertrophic cardiomyopathy. Circulation. 2021;144(Suppl_1):A10372–A10372. doi:10.1161/circ.144.suppl_1.10372
   Google Scholar
• Hundertmark M, Siu AG, Matthews V, et al. A phase 2a trial investigating ninerafaxstat – a novel cardiac mitotrope for the treatment of diabetic cardiomyopathy (IMPROVE-DiCE). Eur Heart J. 2022;43(Supplement_2):ehac544.246. doi:10.1093/eurheartj/ehac544.246
   PubMedGoogle Scholar
• Horowitz JD, Chirkov YY. Perhexiline and hypertrophic cardiomyopathy. Circulation. 2010;122(16):1547–1549. doi:10.1161/circulationaha.110.981464
   PubMed Web of Science ®Google Scholar
• Napoli PD, Giovanni PD, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini D’Abruzzo trimetazidine trial. J Cardiovasc Pharmacol. 2007;50(5):585–589. doi:10.1097/FJC.0b013e31814fa9cb
   PubMed Web of Science ®Google Scholar
• Ho CY, Day SM, Axelsson A, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021;27(10):1818–1824. doi:10.1038/s41591-021-01505-4
   PubMed Web of Science ®Google Scholar
• Kario K, Sun N, Chiang F-T, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in asian patients with hypertension. Hypertension. 2014;63(4):698–705. doi:10.1161/hypertensionaha.113.02002
   PubMed Web of Science ®Google Scholar
• Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387–1398. doi:10.1161/circulationaha.117.033200
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):e783–831. doi:10.1161/CIR.0b013e318223e2bd
   PubMed Web of Science ®Google Scholar
• Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979;42(1):35–42. doi:10.1136/hrt.42.1.35
   PubMedGoogle Scholar
• Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759–769. doi:10.1016/s0140-6736(20)31792-x
   PubMed Web of Science ®Google Scholar
• Mastroianni A, Kahn J. Swinging on the pendulum. Shifting views of justice in human subjects research. Hastings Cent Rep. 2001;31(3):21–28. doi:10.2307/3527551
   PubMed Web of Science ®Google Scholar
• Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy. Ann Intern Med. 2019;170(11):741–748. doi:10.7326/M18-3016
   PubMed Web of Science ®Google Scholar
• Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. journal article; clinical trial protocol. J Am Coll Cardiol. 2022;80(2):95‐108. doi:10.1016/j.jacc.2022.04.048
   Web of Science ®Google Scholar
• Wang A, Heitner SB, Jacoby D, et al. Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (PTS): update from PIONEER open-label extension (PIONEER-OLE) study. Conference Abstract. Eur Heart J. 2019;40:65. doi:10.1093/eurheartj/ehz747.0063
   Web of Science ®Google Scholar